

Freedom of Information Act 2000 - Request Reference FoI/23/134
Dermatology and Respiratory Treatments

Information Requested:

- 1. How many patients were treated in February 2023 (or latest available month) by the Dermatology department with the following drugs:**
 - Abrocitinib (Cibinqo) - 0
 - Baricitinib (Olmiant) - 51
 - Dupilumab (Dupixent) - 75
 - Omalizumab (Xolair) - 0
 - Tralokinumab (Adtralza) - 2
 - Upadacitinib (Rinvoq) - 2

- 2. How many patients were treated in February 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:**
 - Benralizumab (Fasenra) - 44
 - Dupilumab (Dupixent) - 25
 - Omalizumab (Xolair) - 0
 - Reslizumab (Cinqaero) – not used by the UHB
 - Mepolizumab (Nucala) - 73
 - Tezepelumab (Tezspire) 0